{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-070935","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2023-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.371834+00:00","generated_at":"2026-06-07T11:29:32.664820+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Lexeo receives FDA Fast Track and Orphan Drug designations for gene therapy LX2020 in PKP2-ACM","bullets":["FDA granted Fast Track and Orphan Drug designations for LX2020, an AAVrh10 gene therapy for PKP2-ACM.","No approved treatments exist for PKP2-ACM, a prevalent genetic cardiovascular disease.","LX2020 delivers a functional PKP2 gene intravenously to cardiac muscle as a one-time infusion.","Planned Phase 1/2 HEROIC-PKP2 trial: 52-week, open-label, dose-escalating, multicenter with two cohorts (2.0x10^13 and 6.0x10^13 vg/kg).","Orphan Drug offers market exclusivity and tax credits; Fast Track enables expedited FDA review."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-070935","json":"https://secwatch.observer/filing/0000950170-23-070935.json","markdown":"https://secwatch.observer/filing/0000950170-23-070935.md","text":"https://secwatch.observer/filing/0000950170-23-070935.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000095017023070935/0000950170-23-070935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000095017023070935/lxeo-20231218.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T11:29:32.664820+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}